Overexpression of the Ets-1 transcription factor in human breast cancer

The Ets family of transcription factors regulate expression of multiple genes involved in tumour progression. The aim of this study was to investigate the expression of Ets-1 in a large panel of human breast cancers and relate its levels to the parameters of tumour progression and metastasis. Using RT–PCR, Ets-1 mRNA was detected in 30 out of 42 (71%) fibroadenomas and 131 out of 179 (73%) primary breast carcinomas. Similarly, levels of Ets-1 mRNA were not significantly different in fibroadenomas and primary breast carcinomas. Using Western blotting, four forms of the Ets-1 protein were detected, that is, p33, p42, p51 and p52. Levels of both p51 and p52 but not p33 and p42 were present at significantly higher levels in the carcinomas compared to the fibroadenomas (for p51, P<0.007; for p52, P<0.02; Mann–Whitney U-test). Levels of p52, p51 and p33 correlated significantly with uPA protein levels (P<0.01), while only levels of p52 correlated significantly with HER-2/neu protein levels (P<0.01). Using immunohistochemistry, Ets-1 was found predominantly in tumour cells, but was also detected in some stromal cells surrounding tumour islands. We conclude that, while at the mRNA level, Ets-1 was found at similar levels in fibroadenomas and primary breast carcinomas, higher protein levels were detected in the cancers compared to the benign specimens. Since p52, p51 and p33 correlate with uPA levels, these forms of Ets-1 may play a role in breast cancer metastasis.

[1]  Y. Okada,et al.  Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors. , 1999, Journal of neuropathology and experimental neurology.

[2]  B. Wasylyk,et al.  The Ets family of transcription factors. , 1993, European journal of biochemistry.

[3]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[4]  S. Yamashita,et al.  Overexpression of Ets-1 transcription factor in angiosarcoma of the skin. , 2000, Pathology, research and practice.

[5]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[6]  N. Bhat,et al.  Human ETS1 oncoprotein. Purification, isoforms, -SH modification, and DNA sequence-specific binding. , 1992, The Journal of biological chemistry.

[7]  G. Clark,et al.  Amplification of c-erbB-2 and aggressive human breast tumors? , 1988, Science.

[8]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[9]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[10]  C. Sweep,et al.  Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer , 2002, Oncogene.

[11]  A. Nordheim,et al.  Gene regulation by Ets proteins. , 1993, Biochimica et biophysica acta.

[12]  R. Fisher,et al.  Structural inferences of the ETS1 DNA-binding domain determined by mutational analysis. , 1994, Oncogene.

[13]  D. Watson,et al.  Molecular analysis of the ets genes and their products. , 1990, Critical reviews in oncogenesis.

[14]  K. Fujikawa,et al.  The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.

[15]  C. Brinckerhoff,et al.  ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) are auxiliary elements that regulate basal and phorbol-induced transcription. , 1997, Connective tissue research.

[16]  T. Noumi,et al.  Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. , 1995, Oncogene.

[17]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[18]  M. Duffy,et al.  Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer. , 2001, European journal of cancer.

[19]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[20]  J. Nesland,et al.  Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  R. Muschel,et al.  Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line , 1997, Oncogene.

[22]  T. Nakayama,et al.  Expression of the ets-1 Proto-Oncogene in Human Colorectal Carcinoma , 2001, Modern Pathology.

[23]  B. Vandenbunder,et al.  Does the transcription factor c-ets1 take part in the regulation of angiogenesis and tumor invasion? , 1994, Folia biologica.

[24]  S. Galiègue‐Zouitina,et al.  Quantitative and qualitative variation of ETS-1 transcripts in hematologic malignancies. , 1993, Leukemia.

[25]  J. Ghysdael,et al.  Identification of a Ets1 variant protein unaffected in its chromatin and in vitro DNA binding capacities by T cell antigen receptor triggering and intracellular calcium rises. , 1990, Oncogene.

[26]  A. Wellmann,et al.  The Ets‐1 transcription factor is up‐regulated together with MMP 1 and MMP 9 in the stroma of pre‐invasive breast cancer , 2001, The Journal of pathology.

[27]  N. Bhat,et al.  Pleiotropic functions of ETS-1 (Review). , 1996, International journal of oncology.

[28]  S. Shibata,et al.  Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[29]  M. Duffy,et al.  Studies on oestrogen receptor-α and -β mRNA in breast cancer , 2001 .

[30]  B. Wasylyk,et al.  Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. , 1998, Trends in biochemical sciences.

[31]  S. Nakamura,et al.  Immunohistochemical expression of Ets‐1 transcription factor and the urokinase‐type plasminogen activator is correlated with the malignant and invasive potential in meningiomas , 2000, Cancer.

[32]  B. Vandenbunder,et al.  Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development. , 1994, Invasion & metastasis.

[33]  V. Gouyer,et al.  Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. , 1995, The American journal of pathology.

[34]  I. Kola,et al.  Regulation of gene expression by transcription factors Ets‐1 and Ets‐2 , 1994, Molecular reproduction and development.

[35]  R. Li,et al.  The p42 variant of ETS1 protein rescues defective Fas-induced apoptosis in colon carcinoma cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Duffy,et al.  Urokinase Plasminogen Activator: a Prognostic Marker in Breast Cancer including Patients with Axillary Node-negative Disease Materials and Methods Methods Enzymes and Protein Markers , 1997 .

[37]  W. McGuire,et al.  Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.

[38]  G. Mavrothalassitis,et al.  The human ETS1 gene: genomic structure, promoter characterization and alternative splicing. , 1991, Oncogene.

[39]  N. Bhat,et al.  The ets family of genes: molecular biology and functional implications. , 1989, Current topics in microbiology and immunology.

[40]  N. Bhat,et al.  Isoforms of the human ets-1 protein: generation by alternative splicing and differential phosphorylation. , 1990, Oncogene.

[41]  E. Remmers,et al.  Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. , 1993, Journal of immunology.

[42]  B. Vandenbunder,et al.  Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. , 1994, Cancer research.

[43]  W. Muller,et al.  The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis , 2001, Current Biology.

[44]  K. Tanaka,et al.  Signal transduction and transcriptional regulation of angiogenesis. , 2000, Advances in experimental medicine and biology.

[45]  C. Benz,et al.  Targeting the Ets Binding Site of the HER2/neuPromoter with Pyrrole-Imidazole Polyamides* , 2000, The Journal of Biological Chemistry.